Global Cachexia Treatment Market Overview:
Cachexia is a disorder that causes extreme weight loss and muscle wasting and can include loss of body fat. This syndrome affects people who are in the late stages of serious diseases like cancer, HIV or AIDS, COPD, kidney disease, and congestive heart failure (CHF). There is no specific treatment or way to reverse cachexia. The goal of treatment is to improve symptoms and quality of life. Current therapy for cachexia includes appetite stimulants such as megestrol acetate (Megace), drugs, such as dronabinol (Marinol), to improve nausea, appetite, and mood, medications that decrease inflammation and diet changes, nutritional supplements and adapted exercise
- Rise Cases of a Chronic Condition such as Cancer
- Availability of Advanced Healthcare Facilities in Developing Countries
- Huge Investment in R&D in Development of Drugs by Major Market Players
- Adverse Effect Associated with Cachexia Therapy
- Increase in Awareness about the Cachexia Treatment
- Development of Health Care Infrastructure in Developed as well as Developing Countries
- The Stringent Regulatory Requirements and the Long Procedure for FDA Approval
The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to avail a competitive advantage through combined collaborations.
Some of the key players profiled in the report are Pfizer Inc (United States), Merck & Co. Inc. (United States), Aphios Corporation (United States), Benuvia Therapeutics Inc (United States), Alkem Labs (India), Lannett (United States), Ascent Pharmaceuticals, Inc (United States), Akorn Incorporated (United States), Endo International Inc (Ireland), Hikma Pharmaceuticals PLC (United Kingdom) and Teva Pharmaceutical Industries Ltd (Israel). Additionally, following companies can also be profiled that are part of our coverage like Wockhardt (India) and Breckenridge Pharmaceutical, Inc (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Cachexia Treatment market by 2026. Considering Market by Drug, the sub-segment i.e. Dronabinol will boost the Cachexia Treatment market. Considering Market by Route of Administration, the sub-segment i.e. Oral will boost the Cachexia Treatment market. Considering Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacy will boost the Cachexia Treatment market. Considering Market by Drug Class, the sub-segment i.e. Weight Loss Stabilizers will boost the Cachexia Treatment market. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Cachexia Treatment market.
In Dec 2020, Actimed Therapeutics announces that it has been granted US patent US 10,828,270 expanding its intellectual property rights directed to ACM-002 (S-oxprenolol) for the treatment of cancer cachexia. and In Feb 2020, NGM Biopharmaceuticals, Inc. announced the initiation of a Phase 1a/1b clinical study of NGM120, a first-in-class antagonistic antibody that binds glial cell-derived neurotrophic factor receptor alpha-like (GFRAL) and inhibits growth differentiation factor 15 (GDF15) signaling, for the potential treatment of cancer and cancer anorexia/cachexia syndrome (CACS).
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Cachexia Treatment market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Cachexia Treatment market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Cachexia Treatment Treatment Providers, Healthcare Industry, Research Institutes, Government Agencies, Medical Research Laboratories and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.